252 related articles for article (PubMed ID: 22358188)
1. The role of genetics in drug dosing.
Ware N
Pediatr Nephrol; 2012 Sep; 27(9):1489-98. PubMed ID: 22358188
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report.
Brunet M; van Gelder T; Åsberg A; Haufroid V; Hesselink DA; Langman L; Lemaitre F; Marquet P; Seger C; Shipkova M; Vinks A; Wallemacq P; Wieland E; Woillard JB; Barten MJ; Budde K; Colom H; Dieterlen MT; Elens L; Johnson-Davis KL; Kunicki PK; MacPhee I; Masuda S; Mathew BS; Millán O; Mizuno T; Moes DAR; Monchaud C; Noceti O; Pawinski T; Picard N; van Schaik R; Sommerer C; Vethe NT; de Winter B; Christians U; Bergan S
Ther Drug Monit; 2019 Jun; 41(3):261-307. PubMed ID: 31045868
[TBL] [Abstract][Full Text] [Related]
3. Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation.
Zwart TC; Guchelaar HJ; van der Boog PJM; Swen JJ; van Gelder T; de Fijter JW; Moes DJAR
Drug Discov Today; 2021 Nov; 26(11):2527-2546. PubMed ID: 34119665
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.
Andrews LM; Li Y; De Winter BCM; Shi YY; Baan CC; Van Gelder T; Hesselink DA
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1225-1236. PubMed ID: 29084469
[TBL] [Abstract][Full Text] [Related]
5. Practicability of pharmacogenetics in transplantation medicine.
van Gelder T; van Schaik RH; Hesselink DA
Clin Pharmacol Ther; 2014 Mar; 95(3):262-4. PubMed ID: 23995265
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation.
Yu M; Liu M; Zhang W; Ming Y
Curr Drug Metab; 2018; 19(6):513-522. PubMed ID: 29380698
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
[TBL] [Abstract][Full Text] [Related]
8. Immunopharmacologic therapy in renal transplantation.
Shoker AS
Pharmacotherapy; 1996; 16(4):562-75. PubMed ID: 8840362
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of immunosuppressive medications used in renal diseases and transplantation.
de Mattos AM; Olyaei AJ; Bennett WM
Am J Kidney Dis; 1996 Nov; 28(5):631-67. PubMed ID: 9158202
[TBL] [Abstract][Full Text] [Related]
10. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation.
de Jonge H; Naesens M; Kuypers DR
Ther Drug Monit; 2009 Aug; 31(4):416-35. PubMed ID: 19536049
[TBL] [Abstract][Full Text] [Related]
11. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
12. Gene expression signature of tolerance and lymphocyte subsets in stable renal transplants: results of a cross-sectional study.
Moreso F; Torres IB; Martínez-Gallo M; Benlloch S; Cantarell C; Perelló M; Jimeno J; Pujol-Borrell R; Seron D
Transpl Immunol; 2014 Jun; 31(1):11-6. PubMed ID: 24810779
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
Kuypers DR
Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
[No Abstract] [Full Text] [Related]
14. From immunosuppression to tolerance.
Adams DH; Sanchez-Fueyo A; Samuel D
J Hepatol; 2015 Apr; 62(1 Suppl):S170-85. PubMed ID: 25920086
[TBL] [Abstract][Full Text] [Related]
15. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
16. Novel strategies for immune monitoring in kidney transplant recipients.
Fleming JN; Weimert NA
Adv Chronic Kidney Dis; 2010 Sep; 17(5):e63-77. PubMed ID: 20727505
[TBL] [Abstract][Full Text] [Related]
17. Genes and beans: pharmacogenomics of renal transplant.
Murray B; Hawes E; Lee RA; Watson R; Roederer MW
Pharmacogenomics; 2013 May; 14(7):783-98. PubMed ID: 23651025
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy.
Takeuchi A; Kato K; Akashi K; Eto M
Int J Urol; 2018 Feb; 25(2):112-120. PubMed ID: 29105189
[TBL] [Abstract][Full Text] [Related]
19. Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival.
Srinivas TR; Oppenheimer F
Clin Transplant; 2015 Jul; 29(7):644-53. PubMed ID: 25893485
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation].
Vavić N; Ignjatović L; Drasković B; Hrvacević R; Kovacević Z; Paunić Z
Vojnosanit Pregl; 2008 Feb; 65(2):119-27. PubMed ID: 18365668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
